drugset / Trial / NCT02243358

Phase II Study of Chemo-Radiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer

NCT02243358 ↗

Phase 2 Completed 24 enrolled Henry Ford Health System
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the safety and effectiveness of a novel neoadjuvant treatment strategy incorporating 5-fluorouracil/leucovorin with oxaliplatin ( FOLFOX )chemotherapy in combination with chemo-radiation with gemcitabine.

Timeline

Start
2014-02
Primary completion
2017-06-28
Completion
2020-01-14

Drugs

EvaluationDrugModalityDoseRoute
Subject FOLFOX6 Unknown — —
Subject Gemcitabine Small molecule 1000 mg/m2 —
Subject Leucovorin Small molecule — —
Subject Oxaliplatin Small molecule — —